Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial.

Lenon GB, Li KX, Chang YH, Yang AW, Da Costa C, Li CG, Cohen M, Mann N, Xue CC.

Evid Based Complement Alternat Med. 2012;2012:435702. doi: 10.1155/2012/435702. Epub 2012 Feb 20.

2.

Lack of efficacy of a herbal preparation (RCM-102) for seasonal allergic rhinitis: a double blind, randomised, placebo-controlled trial.

Lenon GB, Li CG, Da Costa C, Thien FC, Shen Y, Xue CC.

Asia Pac Allergy. 2012 Jul;2(3):187-94. doi: 10.5415/apallergy.2012.2.3.187. Epub 2012 Jul 25.

4.

Efficacy of 'Itrifal Saghir', a combination of three medicinal plants in the treatment of obesity; A randomized controlled trial.

Kamali SH, Khalaj AR, Hasani-Ranjbar S, Esfehani MM, Kamalinejad M, Soheil O, Kamali SA.

Daru. 2012 Sep 10;20(1):33. doi: 10.1186/2008-2231-20-33.

5.

Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.

Kiesewetter H, Koscielny J, Kalus U, Vix JM, Peil H, Petrini O, van Toor BS, de Mey C.

Arzneimittelforschung. 2000 Feb;50(2):109-17.

PMID:
10719612
6.
7.

Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.

García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.

Clin Ther. 2006 May;28(5):770-82.

PMID:
16861099
8.
9.
11.

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.

Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P.

Int J Obes (Lond). 2007 Mar;31(3):494-9. Epub 2006 Sep 5.

PMID:
16953261
12.

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.

McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD.

Arch Intern Med. 2000 Jul 24;160(14):2185-91.

PMID:
10904462
13.

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.

Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.

J Hum Hypertens. 2002 Jan;16(1):13-9.

14.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
15.

Efficacy of an herbal formulation LI10903F containing Dolichos biflorus and Piper betle extracts on weight management.

Sengupta K, Mishra AT, Rao MK, Sarma KV, Krishnaraju AV, Trimurtulu G.

Lipids Health Dis. 2012 Dec 27;11:176. doi: 10.1186/1476-511X-11-176.

16.

Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial.

Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P.

Clin Nutr. 2008 Jun;27(3):363-70. doi: 10.1016/j.clnu.2008.03.007. Epub 2008 May 12.

PMID:
18468736
17.
18.

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group.

Headache. 2005 Apr;45(4):293-307.

PMID:
15836565
19.
20.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
Items per page

Supplemental Content

Write to the Help Desk